- Barrons.com•19 hours ago
Gilead Sciences (GILD) is set to report earnings next Tuesday, and it can't get much worse than it was last quarter. Guggenheim's Tony Butler and team see more pressure on hepatitis-C profits, but contend Gilead's shares have bottomed. Shares of Gilead Sciences have gained 1.4% to $68.06 at 10:28, while the iShares Nasdaq Biotechnology ETF (IBB) has advanced 0.4% to $296.64.
- Zacks•21 hours ago
Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.
- Zacks•2 days ago
Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||68.34 x 100|
|Ask||68.46 x 1100|
|Day's Range||67.27 - 68.60|
|52 Week Range||65.38 - 101.78|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.86|
|Dividend & Yield||2.08 (3.12%)|
|1y Target Est||N/A|